porozendoОстеопороз и остеопатииOsteoporosis and Bone Diseases2072-26802311-0716Endocrinology Research Centre10.14341/osteo201217-10porozendo-4205Research ArticleСтатьиArticlesНАРУШЕНИЯ КОСТНОГО МЕТАБОЛИЗМА ПРИ СИНДРОМЕ ГИПЕРПРОЛАКТИНЕМИИ У ДЕТЕЙ И ПОДРОСТКОВ (ОБЗОР ЛИТЕРАТУРЫ И СОБСТВЕННЫЕ ДАННЫЕ)DISORDERS OF BONE METABOLISM IN CHILDREN AND ADOLESCENTS WITH HYPERPROLACTINEMIAZhurtovaI. B.

k.m.n., doktorant

zhin07@mail.ruRumyantsevA. G.

d.m.n., professor, direktor

-201215042012151№1 (2012)710Copyright © Zhurtova I.B., Rumyantsev A.G., 20122012Zhurtova I.B., Rumyantsev A.G.Zhurtova I.B., Rumyantsev A.G.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.osteo-endojournals.ru/jour/article/view/4205

У многих больных с пролактинсекретирующими аденомами гипофиза отмечается снижение минеральной плотности кости (МПК), обусловленное преобладанием процессов резорбции в кости и развитием вторичного пролактин-индуцированного гипогонадизма. Нормализация уровня пролактина у подростков способствует повышению МПК, но не приводит к полному восстановлению костной массы. Несмотря на то, что у больных с гиперпролактинемией наблюдается снижение МПК, частота переломов у них не отличается от таковой в общей популяции.

Many patients with prolactin secreting pituitary tumors have a decreased bone mineral density. The bone loss is associated with an increase in bone resorption and is secondary to prolactin-induced hypogonadism. Normalization of prolactin increases the BMD but is not associated with its normalization. Despite low BMD hyperprolactinemic subjects do not demonstrate increase in fractures compared with the general population.

пролактинминеральная плотность костной тканикостная массагиперпролактинемиягипогонадизмprolactinbone mineral densitybone masshyperprolactinemiahypogonadismReferencesHarris J., Stanford P.M., Oakes S.R., Ormandy C.J. (2004) Prolactin and the prolactin receptor: new targets of an old hormone. Ann Med 36: 414—425.Harris J., Stanford P.M., Oakes S.R., Ormandy C.J. (2004) Prolactin and the prolactin receptor: new targets of an old hormone. Ann Med 36: 414—425.Goffin V., Binart N., Touraine P., Kelly P.A. (2002). Prolactin: the new biology of an old hormone. Annu Rev Physiol 64: 47—67.Goffin V., Binart N., Touraine P., Kelly P.A. (2002). Prolactin: the new biology of an old hormone. Annu Rev Physiol 64: 47—67.Фаламеева О.В. (2008). Остеопения и остеопороз в детском, подростковом и юношеском возрасте. Хирургия позвоночника. № 2. С. 65—72.Фаламеева О.В. (2008). Остеопения и остеопороз в детском, подростковом и юношеском возрасте. Хирургия позвоночника. № 2. С. 65—72.Theintz G., Buchs B., Rizzoli R., Slosman D., Clavien H., Sizonenko P.C. & Bonjour J.P. (1992). Longitudinal monitoring of bone mass ocumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. Journal of Clinical Endocrinology and Metabolism, Vol. 75, 1060—1065.Theintz G., Buchs B., Rizzoli R., Slosman D., Clavien H., Sizonenko P.C. & Bonjour J.P. (1992). Longitudinal monitoring of bone mass ocumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. Journal of Clinical Endocrinology and Metabolism, Vol. 75, 1060—1065.Bonjour J.P., Theintz G., Buchs B., Sloman D. & Rizzoli R. (1991). Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. Journal of Clinical Endocrinology and Metabolism, Vol. 73, 555—563.Bonjour J.P., Theintz G., Buchs B., Sloman D. & Rizzoli R. (1991). Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. Journal of Clinical Endocrinology and Metabolism, Vol. 73, 555—563.Eriksen E.F. & Langdahl B.L. (1997). The pathogenesis of osteoporosis. Hormone Research, 48 (Suppl. 5), 78—82.Eriksen E.F. & Langdahl B.L. (1997). The pathogenesis of osteoporosis. Hormone Research, 48 (Suppl. 5), 78—82.Teegarden D., Proulx W.R., Martin B.R.J., et al. Peak bone mass in young women. J Bone Miner Res 1995; Vol. 10: 711—715.Teegarden D., Proulx W.R., Martin B.R.J., et al. Peak bone mass in young women. J Bone Miner Res 1995; Vol. 10: 711—715.Weaver C.M. (2002). Adolescence: the period of dramatic bone growth. Endocrine Vol.17: 43—48.Weaver C.M. (2002). Adolescence: the period of dramatic bone growth. Endocrine Vol.17: 43—48.Gordon C.M., Nelson L.M. (2003). Amenorrhea and bone health in adolescents and young women. Curr Opin Obstet Gynecol. Vol.15(5): 377—384.Gordon C.M., Nelson L.M. (2003). Amenorrhea and bone health in adolescents and young women. Curr Opin Obstet Gynecol. Vol.15(5): 377—384.Думанская Ю.А., Щербавская Э.А. (2008). Влияние нарушений менструальной функции в пубертатном периоде на состояние костной ткани (Обзор литературы). Проблемы репродукции. № 2. С. 17—21.Думанская Ю.А., Щербавская Э.А. (2008). Влияние нарушений менструальной функции в пубертатном периоде на состояние костной ткани (Обзор литературы). Проблемы репродукции. № 2. С. 17—21.Charoenphandhu N., Krishnamra N. (2007). Prolactin is an important regulator of intestinal calcium transport. Can J Physiol Pharmacol Vol.85: 569—581.Charoenphandhu N., Krishnamra N. (2007). Prolactin is an important regulator of intestinal calcium transport. Can J Physiol Pharmacol Vol.85: 569—581.Biller B.M., Baum H.B., Rosenthal D.I., Saxe V.C., Charpie P.M., Klibanski A. (1992). Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab Vol.75: 692—697.Biller B.M., Baum H.B., Rosenthal D.I., Saxe V.C., Charpie P.M., Klibanski A. (1992). Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab Vol.75: 692—697.Kayath M.J., Lengyel A.M., Vieira J.G. (1993). Prevalence and magnitude of osteopenia in patients with prolactinoma. Braz J Med Biol Res Vol. 26: 933—941.Kayath M.J., Lengyel A.M., Vieira J.G. (1993). Prevalence and magnitude of osteopenia in patients with prolactinoma. Braz J Med Biol Res Vol. 26: 933—941.Kumar R., Abboud C.F., Riggs B.L. (1980). The effect of elevated prolactin levels on plasma 1, 25-dihydroxyvitamin D and intestinal absorption of calcium. Mayo Clin Proc Vol. 55: 51—53.Kumar R., Abboud C.F., Riggs B.L. (1980). The effect of elevated prolactin levels on plasma 1, 25-dihydroxyvitamin D and intestinal absorption of calcium. Mayo Clin Proc Vol. 55: 51—53.Schlechte J.A., Sherman B., Martin R. (1983). Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab Vol. 56: 1120—1123.Schlechte J.A., Sherman B., Martin R. (1983). Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab Vol. 56: 1120—1123.Schlechte J., Walkner L., Kathol M. (1992). A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab Vol. 75: 698—703.Schlechte J., Walkner L., Kathol M. (1992). A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab Vol. 75: 698—703.Храмцова С.Н., Щеплягина Л.А., Арсеньева Е.И., Алатырцев В.В., Моисеева Т.Ю. (2006). Возрастные закономерности изменения биохимических маркеров костного ремоделирования у детей 5-16 лет. Вопросы современной педиатрии. № 5. С. 620.Храмцова С.Н., Щеплягина Л.А., Арсеньева Е.И., Алатырцев В.В., Моисеева Т.Ю. (2006). Возрастные закономерности изменения биохимических маркеров костного ремоделирования у детей 5-16 лет. Вопросы современной педиатрии. № 5. С. 620.Мальцев С.В., Архипова Н.Н. (2008). Остеопороз — «педиатрическая проблема с гериатрическими последствиями» практическая медицина. № 31. С. 14-17.Мальцев С.В., Архипова Н.Н. (2008). Остеопороз — «педиатрическая проблема с гериатрическими последствиями» практическая медицина. № 31. С. 14-17.Di Somma C., Colao A., Di Sarno A. et al. (1998). Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab Vol. 83: 807—813.Di Somma C., Colao A., Di Sarno A. et al. (1998). Bone marker and bone density responses to dopamine agonist therapy in hyperprolactinemic males. J Clin Endocrinol Metab Vol. 83: 807—813.Colao A., Di Somma C., Loche S., Di Sarno A., Klain M., Pivonello R., Pietrosante M., Salvatore M., Lombardi G (2000). Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf) Vol. 52: 319—327.Colao A., Di Somma C., Loche S., Di Sarno A., Klain M., Pivonello R., Pietrosante M., Salvatore M., Lombardi G (2000). Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf) Vol. 52: 319—327.Galli-Tsinopoulou A., Nousia-Arvanitakis S., Mitsiakos G., Karamouzis M., Dimitriadis A. (2000). Osteopenia in children and adolescents with hyperprolactinemia. J Pediatr Endocrinol Metab. Vol. 13(4): 439—41.Galli-Tsinopoulou A., Nousia-Arvanitakis S., Mitsiakos G., Karamouzis M., Dimitriadis A. (2000). Osteopenia in children and adolescents with hyperprolactinemia. J Pediatr Endocrinol Metab. Vol. 13(4): 439—41.Naliato E.C., Farias M.L., Braucks G.R., Costa F.S., Zylberberg D., Violante A.H. (2005). Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest Vol. 28: 12—17.Naliato E.C., Farias M.L., Braucks G.R., Costa F.S., Zylberberg D., Violante A.H. (2005). Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest Vol. 28: 12—17.Shaarawy M., El-Dawakhly A.S., Mosaad M., El-Sadek M.M. (1999). Biomarkers of bone turnover and bone mineral density in hyperprolactinemic amenorrheic women. Clin Chem Lab Med Vol. 37: 433—438.Shaarawy M., El-Dawakhly A.S., Mosaad M., El-Sadek M.M. (1999). Biomarkers of bone turnover and bone mineral density in hyperprolactinemic amenorrheic women. Clin Chem Lab Med Vol. 37: 433—438.Naliato E.C., Violante A.H., Caldas D. et al. (2008). Bone density in women with prolactinoma treated with dopamine agonists. Pituitary Vol. 11: 21—28.Naliato E.C., Violante A.H., Caldas D. et al. (2008). Bone density in women with prolactinoma treated with dopamine agonists. Pituitary Vol. 11: 21—28.Sartorio A., Conti A., Ambrosi B., Muratori M., Morabito F., Faglia G. (1990). Osteocalcin levels in patients with microprolactinoma before and during medical treatment. J Endocrinol Invest Vol. 13: 419—422.Sartorio A., Conti A., Ambrosi B., Muratori M., Morabito F., Faglia G. (1990). Osteocalcin levels in patients with microprolactinoma before and during medical treatment. J Endocrinol Invest Vol. 13: 419—422.Bachrach L.K., Katzman D.K., Litt I.F., Guido D., Marcus R. (1991). Recovery from osteopenia in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab Vol. 72: 602—606.Bachrach L.K., Katzman D.K., Litt I.F., Guido D., Marcus R. (1991). Recovery from osteopenia in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab Vol. 72: 602—606.do Carmo I., Mascarenhas M., Macedo A et al. (2007). A study of bone density change in patients with anorexia nervosa. Eur Eat Disord Rev Vol. 15: 457—462.do Carmo I., Mascarenhas M., Macedo A et al. (2007). A study of bone density change in patients with anorexia nervosa. Eur Eat Disord Rev Vol. 15: 457—462.Warren M.P., Brooks-Gunn J., Fox R.P., Lancelot C., Newman D., Hamilton W.G. (1991). Lack of bone accretion and amenorrhea: evidence for a relative osteopenia in weight bearing bones. J Clin Endocrinol Metab Vol. 72: 847—853.Warren M.P., Brooks-Gunn J., Fox R.P., Lancelot C., Newman D., Hamilton W.G. (1991). Lack of bone accretion and amenorrhea: evidence for a relative osteopenia in weight bearing bones. J Clin Endocrinol Metab Vol. 72: 847—853.Biller B.M., Coughlin J.F., Saxe V., Schoenfeld D., Spratt D.I., Klibanski A. (1991). Osteopenia in women with hypothalamic amenorrhea: a prospective study. Obstet Gynecol Vol. 78: 996—1001.Biller B.M., Coughlin J.F., Saxe V., Schoenfeld D., Spratt D.I., Klibanski A. (1991). Osteopenia in women with hypothalamic amenorrhea: a prospective study. Obstet Gynecol Vol. 78: 996—1001.Shibli-Rahhal A., Schlechte J. (2009). The effects of hyperprolactinemia on bone and fat Pituitary Vol. 12: 96—104.Shibli-Rahhal A., Schlechte J. (2009). The effects of hyperprolactinemia on bone and fat Pituitary Vol. 12: 96—104.Tyson D., Reggiardo D., Sklar C. & David R. (1993). Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy. American Journal of Disease Children, Vol. 147, 1057—1061.Tyson D., Reggiardo D., Sklar C. & David R. (1993). Prolactin-secreting macroadenomas in adolescents. Response to bromocriptine therapy. American Journal of Disease Children, Vol. 147, 1057—1061.Colao A., Loche S., Cappa M., Di Sarno A., Landi M.L., Sarnacchiaro F., Facciolli G. & Lombardi G. (1998b) Prolactinomas in children and adolescents. Clinical presentation and longterm follow-up. Journal of Clinical Endocrinology and Metabolism, Vol. 83, 2777—2780.Colao A., Loche S., Cappa M., Di Sarno A., Landi M.L., Sarnacchiaro F., Facciolli G. & Lombardi G. (1998b) Prolactinomas in children and adolescents. Clinical presentation and longterm follow-up. Journal of Clinical Endocrinology and Metabolism, Vol. 83, 2777—2780.Castelo-Branco C., Rovira M., Pons F. et al. (1996). The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas Vol. 23: 307—312.Castelo-Branco C., Rovira M., Pons F. et al. (1996). The effect of hormone replacement therapy on bone mass in patients with ovarian failure due to bone marrow transplantation. Maturitas Vol. 23: 307—312.Prior J.C., Vigna Y.M., Wark J.D. et al. (1997). Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res Vol. 12: 1851—1863.Prior J.C., Vigna Y.M., Wark J.D. et al. (1997). Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res Vol. 12: 1851—1863.

The authors declare that there are no conflicts of interest present.